ASLAN Pharmaceuticals

You are now leaving our web site.
I understand

Transforming the treatment of Asia prevalent cancer

ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.

Our Company

Led by a management team with extensive global pharma and biotech experience, ASLAN collaborates with internationally renowned experts and institutions to develop drugs – turning ground breaking research into effective therapies for those in need.

Learn More About Our Team

Therapeutic Areas

We focus on Asia prevalent tumour types, including gastric cancer, biliary tract cancer and breast cancer. As few effective therapies exist to treat these diseases, there is a significant unmet need globally.

Learn More About Our Drugs

Our Therapeutic Areas include: Cholangiocarcinoma Gastric cancer Breast cancer

Developing in Asia for global markets

Through our presence in Singapore, Taiwan, China and Australia, we develop drugs across the Asia Pacific region, then leverage the data for global registration, with the potential for accelerated approvals in countries where these indications are considered orphan diseases.

Learn More

We have offices in Singapore, Taipei, Shanghai and Australia, and conduct regional clinical development programmes across Asia.

3 January 2018

ASLAN Pharmaceuticals acquires full global commercial rights for varlitinib from Array BioPharma

Read more
1 June 2017

ASLAN Pharmaceuticals commences first day of trading on the Taipei Exchange

Read more
24 April 2017

ASLAN Pharmaceuticals initiates global pivotal study for varlitinib in biliary tract cancer

Read more
20 February 2017

ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer

Read more
23 January 2017

ASLAN receives approval to list on the Taipei Exchange

Read more
4 July 2016

ASLAN raises US$23 million in pre-IPO financing round

Read more
24 June 2016

ASLAN receives Orphan Drug Designation for varlitinib in gastric cancer

Read more
8 April 2016

ASLAN opens China office

Read more
25 March 2016

ASLAN named Asian Biotech of the Year

Read more
7 January 2016

ASLAN Pharmaceuticals announces final close of US$43 million Series C round

Read more
7 December 2015

ASLAN raises US$34 million in Series C funding

Read more
13 August 2015

ASLAN001 receives Orphan Drug Designation from the FDA in cholangiocarcinoma

Read more
16 July 2015

ASLAN signs MOU with National Cancer Centre Singapore to research and develop therapies for Asia prevalent tumour types

Read more
16 March 2015

ASLAN announces positive phase 1 results with ASLAN002

Read more
6 February 2014

ASLAN opens office in Taipei

Read more
10 October 2013

ASLAN completes Series B financing raising US$22 million

Read more
28 May 2013

ASLAN announces positive data with ASLAN001 in gastric cancer phase 2 study

Read more
21 May 2012

ASLAN announces a global inlicensing agreement with Almirall for ASLAN003 in rheumatoid arthritis

Read more
3 November 2011

ASLAN enters innovative partnership with Bristol-Myers Squibb to license and develop oncology compound ASLAN002

Read more
13 July 2011

ASLAN inlicenses ASLAN001, a phase 2 oncology compound, from Array Biopharma

Read more
21 April 2011

ASLAN completes Series A fundraising providing US$12 million to develop first compounds

Read more
27 July 2010

ASLAN closes seed round raising US$2 million

Read more

Our History

Founded in 2010, ASLAN has rapidly established a strong track record in oncology-focused product development. Since its founding, ASLAN has raised over US$130 million in financing, formed innovative partnerships with pharmaceutical industry leaders and developed four therapeutic medicines that target cancers for which there are few effective treatments.

View Our Milestones